产品
  • 产品
  • 供应商
  • 采购
  • 资讯
  • 会展
首页 制药产品大全 药品制剂 Enoxaparin sodi...

Enoxaparin sodium injection

2026-02-27
成都市

产品详情

Enoxaparin sodium injection
心脑血管及循环系统类制剂
北美洲,中/南美洲,西欧,东欧,大洋洲,亚洲,中东,非洲

产品描述

Active ingredients: enoxaparin sodium, molecular weight: average molecular weight is between 3800-5000 daltons.
Description: clear, colorless to pale yellow clear liquid.      

Dosage Form: liquid injection.                                                                           
Indications:

1. Prophylaxis of venous thromboembolic diseases (the generation of venous thrombosis), specially orthopedic or general surgery-related thrombosis;

2. For acute deep vein thrombosis, with or without pulmonary embolism and when symptoms are not obvious. Exclude pulmonary embolism which requires surgery and thrombolytic therapy;

3. Treatment of unstable Angina and Non-Q-Wave Myocardial infarction, when concurrently administered with aspirin;

4. Hemodialysis in vitro circulation, to prevent thrombosis.
Strength:0.6ml:6000AxaIU

Storage: Keep airtight in a cool place.
Packaging: 10 bottles/box, 100 boxes/carton (Can be customized based on customer's order.)

Shelf Life: 24months.

四川宏明博思药业有限公司
访问店铺
注册资本
公司地址
联系人

公司简介

四川宏明博思药业有限公司成立于2013年,专注于原料药和制剂的生产。现有员工400余人,主要生产高端剂型如注射剂、冻干粉针剂、片剂和胶囊剂。宏明博思的冻干粉针制剂生产线已获得EU GMP,并通过巴西ANVISA现场检查。目前四川宏明博思冻干粉针制剂的多个产品在巴西、智利、秘鲁、危地马拉、泰国、菲律宾、马来西亚、南非、澳大利亚等开展注册中。Sichuan Omnis Pharmaceutical Co., Ltd. was established in 2013, focusing on the manufacture of FDFs and APIs, located in Sichuan Chengdu, China. It currently has more than 400 employees and mainly produces high-end dosage forms such as injections, lyophilized powder injections, tablets and capsules. Omnis has granted China/EU/ANVISA/PICs GMP for lyophilized powder injection line. Currently, multiple products of lyophilized powder injection are undergoing registration in Brazil, Chile, Peru, Guatemala, Thailand, the Philippines, Malaysia, South Africa, Australia, and other countries.
业务类型:
成立日期:
年营业额:
主营产品类别: